Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.33 USD | +3.21% | -10.46% | -34.25% |
May. 14 | Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target | MT |
May. 10 | UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.25% | 2.76B | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+48.60% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics : JPMorgan Upgrades Amicus Therapeutics to Overweight From Neutral, Price Target at $16